Search details
1.
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
Exp Parasitol
; 233: 108205, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34968460
2.
Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.
Parasitol Res
; 121(7): 2129-2140, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35614147
3.
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection.
Microb Pathog
; 151: 104745, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33485994
4.
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Med Microbiol Immunol
; 210(2-3): 133-147, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33870453
5.
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
Exp Parasitol
; 221: 108059, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33338468
6.
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection.
Parasitol Res
; 120(12): 4037-4047, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34664113
7.
Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Parasitol Res
; 120(1): 321-335, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33191446
8.
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Cell Immunol
; 356: 104194, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32827943
9.
Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
Cytokine
; 129: 155031, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32062145
10.
Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
Parasite Immunol
; 42(12): e12784, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32772379
11.
Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells.
Parasitol Res
; 119(8): 2609-2622, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32535734
12.
Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Exp Parasitol
; 199: 30-37, 2019 Apr.
Article
in English
| MEDLINE | ID: mdl-30817917
13.
Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
Cell Immunol
; 331: 67-77, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29871740
14.
A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
Cytokine
; 111: 131-139, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30142534
15.
Antigenicity, immunogenicity and protective efficacy of a conserved Leishmania hypothetical protein against visceral leishmaniasis.
Parasitology
; 145(6): 740-751, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29113597
16.
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
Exp Parasitol
; 186: 24-35, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29448040
17.
Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Exp Parasitol
; 169: 34-42, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-27427166
18.
In vitro and in vivo antileishmanial activity of ß-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis.
Parasite
; 28: 38, 2021.
Article
in English
| MEDLINE | ID: mdl-33851916
19.
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.
NPJ Vaccines
; 5: 75, 2020.
Article
in English
| MEDLINE | ID: mdl-32821440
20.
A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model.
Parasite
; 27: 29, 2020.
Article
in English
| MEDLINE | ID: mdl-32351209